Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced that it has been granted a U.S. patent by the United States Patent and Trademark Office (“USPTO”); the patent is in support of Cybin’s CYB003 program. According to the announcement, the newly … Continue reading InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notification of Additional US Patent for Proprietary Deuterated Psilocybin Analog Program